Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Carcinoma, Hepatocellular 29Neoplasms 18Neoplasm Metastasis 14Melanoma 14Stomach Neoplasms 13Esophageal Neoplasms 13Colorectal Neoplasms 12Nasopharyngeal Carcinoma 11Esophageal Squamous Cell Carcinoma 10Triple Negative Breast Neoplasms 9Head and Neck Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Recurrence 8Breast Neoplasms 8Rectal Neoplasms 7Pancreatic Neoplasms 7Lung Neoplasms 7Carcinoma, Renal Cell 7Biliary Tract Neoplasms 7Small Cell Lung Carcinoma 6Colonic Neoplasms 5Cholangiocarcinoma 5Sarcoma 4Ovarian Neoplasms 4Locally Advanced Rectal Cancer 4Liver Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3

Interventions

dostarlimab 2Radiotherapy 2Oxaliplatin 2sintilimab 1irinotecan sucrosofate 1XELOX 1Neoadjuvant Therapy 1Immune Checkpoint Inhibitors 1Endoscopic Mucosal Resection 1Drug Therapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Rectal Cancer (LARC) × Immune Checkpoint Inhibitors × Clear all
NCT07040098 2025-06-26

STELLARIII

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
228 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡